

2021

Therapeutic efficacy of mesenchymal stem cells for cardiovascular diseases

Dragana Radoje Miloradovic

UNIVERSITY OF KRAGUJEVAC, FACULTY OF MEDICAL SCIENCES, DEPARTMENT OF GENETICS, SERBIA

Dragica Radoje Pavlovic

UNIVERSITY OF KRAGUJEVAC, FACULTY OF MEDICAL SCIENCES, DEPARTMENT OF GENETICS, SERBIA

Miodrag Bozidar Stojkovic

UNIVERSITY OF KRAGUJEVAC, FACULTY OF MEDICAL SCIENCES, DEPARTMENT OF GENETICS, SERBIA


Sanja Bratislav Bojic

NEWCASTLE UNIVERSITY, SCHOOL OF COMPUTING, NEWCASTLE UPON TYNE, UK

Vladislav Bogdan Volarevic

UNIVERSITY OF KRAGUJEVAC, FACULTY OF MEDICAL SCIENCES, DEPARTMENT OF MICROBIOLOGY AND IMMUNOLOGY, CENTER FOR MOLECULAR MEDICINE AND STEM CELL RESEARCH, SERBIA

Follow this and additional works at: <https://scholar.valpo.edu/jmms>

 [Click the next page for additional authors](#)
Part of the [Cardiology Commons](#), [Circulatory and Respiratory Physiology Commons](#), [Integrative Medicine Commons](#), and the [Medical Cell Biology Commons](#)

Recommended Citation

Miloradovic, Dragana Radoje; Pavlovic, Dragica Radoje; Stojkovic, Miodrag Bozidar; Bojic, Sanja Bratislav; Volarevic, Vladislav Bogdan; Jankovic, Marina Milosav Gazdic; and Ljubic, Biljana Tomislav (2021)

"Therapeutic efficacy of mesenchymal stem cells for cardiovascular diseases," *Journal of Mind and Medical Sciences*: Vol. 8 : Iss. 2 , Article 3.

DOI: 10.22543/7674.82.P179190

Available at: <https://scholar.valpo.edu/jmms/vol8/iss2/3>

This Review Article is brought to you for free and open access by ValpoScholar. It has been accepted for inclusion in *Journal of Mind and Medical Sciences* by an authorized administrator of ValpoScholar. For more information, please contact a ValpoScholar staff member at scholar@valpo.edu.

Therapeutic efficacy of mesenchymal stem cells for cardiovascular diseases

Authors

Dragana Radoje Miloradovic, Dragica Radoje Pavlovic, Miodrag Bozidar Stojkovic, Sanja Bratislav Bojic, Vladislav Bogdan Volarevic, Marina Milosav Gazdic Jankovic, and Biljana Tomislav Ljubic

Therapeutic efficacy of mesenchymal stem cells for cardiovascular diseases

Dragana Radoje Miloradovic¹, Dragica Radoje Pavlovic¹, Miodrag Bozidar Stojkovic^{1,2,3}, Sanja Bratislav Bojic⁴, Vladislav Bogdan Volarevic⁵, Marina Milosav Gazdic Jankovic¹, Biljana Tomislav Ljubic^{1*}

¹UNIVERSITY OF KRAGUJEVAC, FACULTY OF MEDICAL SCIENCES, DEPARTMENT OF GENETICS, SERBIA

²SPEBO MEDICAL FERTILITY HOSPITAL, LESKOVAC, SERBIA

³EATON PEABODY LABORATORIES AND DEPARTMENT OF OTOLARYNGOLOGY, MASSACHUSETTS EYE AND EAR, BOSTON, MASSACHUSETTS; DEPARTMENT OF OTOLARYNGOLOGY – HEAD AND NECK SURGERY, HARVARD MEDICAL SCHOOL, BOSTON, MASSACHUSETTS, USA.

⁴NEWCASTLE UNIVERSITY, SCHOOL OF COMPUTING, NEWCASTLE UPON TYNE, UK

⁵UNIVERSITY OF KRAGUJEVAC, FACULTY OF MEDICAL SCIENCES, DEPARTMENT OF MICROBIOLOGY AND IMMUNOLOGY, CENTER FOR MOLECULAR MEDICINE AND STEM CELL RESEARCH, SERBIA

ABSTRACT



Despite the improvements in pharmacological and surgical treatments, cardiovascular diseases (CVDs) are the number one cause of death worldwide. During the last two decades, the search for new therapies has been revolutionized with the growing knowledge of stem cell biology. Due to their huge differentiation capacity and paracrine effects, mesenchymal stem cells (MSCs) are a promising tool for the treatment of CVDs. The encouraging outcomes of preclinical studies using MSCs as a treatment for diseased myocardium have set the scene for worldwide clinical trials. In this review, we overview either complete or ongoing clinical trials using MSCs for the therapy of CVDs. In particular, we analyze the biological properties of MSCs, elucidate recent clinical findings and clinical trial phases of investigation, highlight clinical therapeutic effects of MSCs, and discuss challenges towards the clinical use of these cells in the therapy of CVDs.

Category: Review

Received: June 17, 2021

Accepted: August 10, 2021

Published: October 10, 2021

Keywords:

mesenchymal stem cells, clinical trial, cardiovascular diseases

***Corresponding author:**

Biljana Tomislav Ljubic,

University of Kragujevac, Faculty of Medical Sciences,
Department of Genetics, 69 Svetozar Markovic Street, 34000
Kragujevac, Serbia

E-mail: bljujic74@gmail.com

Introduction

The leading cause of mortality and disability worldwide are cardiovascular diseases (CVDs), systemic circulatory diseases which arise in the field of abnormal heart and blood vessels. CVDs accounted for approximately 31% of all global deaths, causing 17.8 million deaths in 2017, mostly in low- and middle-income countries [1]. Hypertension, diabetes, hyperlipidemia, tobacco use, obesity, a sedentary lifestyle and the harmful use of alcohol are the pivotal risk factors for CVDs occurrence [2]. In spite of the notable progress in medical and surgical therapies, CVDs continue to exhibit high rates of morbidity and mortality. Drug therapy problems and cardiotoxicity are some of the biggest barriers to pharmacotherapy in the treatment of CVDs [3]. Fever, postoperative bleeding, stroke, atrial fibrillation, renal failure, respiratory distress, cardiogenic shock, and

myocardial infarction type 5- represent the ordinary complications that can occur as a consequence of the surgical treatment in patients with CVDs [4,5]. Likewise, these therapeutic problems prolong hospital stays and increase the overall burden of healthcare expenditures. Therefore, a certainty has developed for therapy that it has fewer side effects, lower mortality rates, fewer complications, as well as better and secure recoveries of patients.

With the recent advances in the field of stem cell biology [6], it was suggested that stem cells might be exploited to repair damaged cardiac tissue and blood vessels. In this review, we overview either complete or ongoing clinical trials using MSCs for CVDs conducted worldwide. In particular, we analyze the biological properties of MSCs, elucidate recent clinical findings and clinical trial phases of investigation, highlight the clinical therapeutic effects of MSCs, and discuss the

challenges towards the clinical use of these cells in the therapy of CVDs.

Discussions

Mesenchymal stem cells - a new therapeutic strategy for cardiovascular diseases

Mesenchymal stem cells are adult stem cells that can be isolated from nearly every tissue type in the adult or infant human body [7] such as bone marrow [8], adipose tissue [9], peripheral blood [10], synovium, and synovial fluid [11], menstrual blood and endometrium [12], skin [13], the dental pulp [14], umbilical cord blood [15], Wharton's jelly [16], amniotic fluid and placenta [17], breast milk [18], and urine [19] (Figure 1). Usually, MSCs are plastic-adherent, fibroblast-like cells that are qualified to differentiate to osteoblasts, chondroblasts, and adipocytes in vitro [20]. MSCs are able to transdifferentiate into non-mesodermal cells such as neurons or astrocytes, hepatocytes, and pancreatic cells under specified culture conditions [21]. Due to the absence of an MSC-specific marker, the Mesenchymal and Tissue Stem Cell Committee of the International Society for Cellular Therapy proposed a minimum number of criteria for the phenotypic characterization of human MSCs [22]. MSCs are positive for CD105, CD73, and CD90 and characterized by the lack of expression CD45, CD34, CD14, CD11b, CD79 alpha or CD19, and HLA-DR surface molecules [22].

A tremendous number of animal models that resemble the pathology of CVDs in humans have demonstrated not only the therapeutic efficacy of culture-expanded MSCs, but also their mechanism of action that may be of relevance to the future widespread clinical use of MSCs [23-30]. MSCs represent a cellular source for cardiovascular repair since they are able to differentiate into cardiomyocytes (CMs) [31-33], endothelial cells (ECs) [34-36], and smooth muscle cells (SMCs) [36-38] (Figure 1). However, very few MSCs are found engrafted at the site of injury linked to the degree of functional recovery [7,21]. Thus, the vast majority of recently published studies revealed that the beneficial effects and utilization of MSCs in CVDs will be also based on their ability to produce a wide range of cytokines, chemokines, and growth factors [39] that resolve inflammation [24], inhibit apoptosis [26,27] and fibrosis [26,40], promote angiogenesis [25,29,40-50], and induce endogenous cardiomyocyte regeneration [43-45] (Figure 1).

MSCs attenuate cardiac injury through the production of several pro-angiogenic factors such as the placental growth factor (PGF), vascular endothelial growth factor (VEGF), insulin-like growth factor (IGF-1), and basic fibroblast growth factor (bFGF), which facilitate tissue regeneration by inducing the proliferation of ECs and by promoting neovascularization [25,26,29,40-42,46]. In cell-

to-cell contact and through the production of soluble mediators, MSCs can alter the function of all immune cells that have a key role in the pathogenesis of CVDs [47,48]. MSCs regulate the proliferation, activation, and effector function of T lymphocytes, professional antigen-presenting cells (dendritic cells, macrophages, B lymphocytes), NK cells, and NKT cells [48,49]. Thus, the improvement of a wide range of cardiac functions (increased EF, decreased in scar tissue, reversed remodeling, ameliorated contractility, augmented heart perfusion, and improved blood vessel density) [30,41,50-52], indicates the possible use of MSCs in the therapy of CVDs. Over the past few years, MSCs were used in a broad range of clinical trials exploring the therapeutic effects of MSCs in the treatment of coronary artery disease, heart failure, and cardiomyopathy (Table 1), as well as peripheral artery disease and stroke (Table 2) and their findings, were analyzed in this review.




Figure 1. The main mechanisms responsible for MSC-based treatment of CVDs. Transplanted MSCs can contribute to cardiovascular repair and regeneration by forming endothelial cells (ECs), smooth muscle cells (SMCs) and cardiomyocytes (CMs) (differentiation). Additionally, MSCs produce a broad range of cytokines, chemokines, and growth factors that resolve inflammation, inhibit apoptosis and fibrosis, promote angiogenesis, and induce endogenous cardiomyocyte regeneration.

MSC-based therapy of coronary artery disease

One study showed that one month after ST-elevation MI (STEMI), the intracoronary infusion of autologous bone marrow-derived MSCs (BM-MSCs) provided a modest improvement in the left ventricular ejection fraction (LVEF) at six-months follow-up by single-photon emission computed tomography [51]. It is also important to notice that there was no treatment-related toxicity during the administration of MSCs, and no serious cardiovascular complications throughout the follow-up [51]. For the reason that cell therapy is not possible at an early phase of remodeling, growing evidence recommends that the prevention of LV remodeling by MSCs transplantation throughout the late dilation phase is practical [53]. As a proper technique for supplementing primary percutaneous coronary intervention (PCI), several research groups investigated intracoronary transplantation of autologous BM-MSCs [53,54].

In patients with acute anterior wall MI, they found that the administration of autologous BM-MSC at one month after PCI is tolerable and safe with a significant improvement in LVEF one month and four months after the stem cell treatment [54]. Serial cardiac echocardiographic monitoring displayed that the improvement of the cardiac function was kept nearly six months after the procedure [53]. At the 16–36-month follow-up, the implanted cardioverter defibrillators failed to discover sustained or non-sustained ventricular arrhythmia in any patient with previous anteroseptal MI who underwent intracoronary transplantation of autologous BM-MSCs [55]. MSCs may be used as an allogeneic graft for the treatment of CVDs, due to the lack of various major histocompatibility complex and costimulatory cell-surface antigens [56,57].

In a randomized, double-blind, placebo-controlled study, Hare and co. showed that the intravenous administration of allogeneic BM-MSCs (0.5, 1.6, and 5.0×10^6 MSCs/kg body weight) is well-tolerated, safe, and effective in patients after acute anterior MI [58]. In the same study, they showed that LVEF, forcible expiratory volume and global symptom score were significantly improved, while the incidence of arrhythmia was reduced in MSC-treated compared to placebo-treated post-infarction subjects [58]. In a double-blind, randomized controlled trial of Gao and co., it was elucidated that the intracoronary application of WJMSCs in patients with acute STEMI significantly increased myocardial viability, perfusion within the infarcted territory, as well as the global LVEF [52]. WJMSC infusion averted post-infarct LV adverse remodeling, as evidenced by the modifications in the LV end-systolic volumes (LVESV) and end-diastolic volumes (LVEDV) at 18 months [52] (Table 1).

MSCs as novel therapeutic agents in the treatment of heart failure

It was demonstrated that intra-myocardial injections of autologous BM-MSCs were safe and improved the myocardial function in patients with ischemic HF, compared to placebo in terms of LVEF, stroke volume, myocardial mass, and cardiac output [59,60]. The administration of BM-MSCs, as evidenced by progressive decreases in both LVEDV and LVESV, led to reverse LV remodeling, indicating an improved outcome in patients with HF [59,60].

In patients with ischemic or non-ischemic HF, Perin and co. evaluated the feasibility and safety of different doses (25, 75, or 150 million cells) of immune-selected allogeneic mesenchymal precursors cells (MPCs) [61]. They found that the transendocardial route of delivery for MPCs therapy was safe and well-tolerated without clinically symptomatic immune responses [61]. The highest MPCs dose diminished the adverse cardiac events and reversed certain parameters of cardiac remodeling in HF patients [61]. Nevertheless, further studies are needed to explore the relationship between the number of intramyocardial injections, the number of stem cells and the volume administered, and their impact on the observed reverse remodeling outcome. Kastrup and co. formed a centralized production of an allogeneic Cardiology Stem Cell Centre adipose-derived stromal cell (CSCC_ASC) product from healthy donors that delivered directly to the myocardium into the border area of infarcted tissue and showed safety, feasibility, and a tendency toward clinical efficacy in ten patients with ischemic heart disease and ischemic HF [62]. It is important to notice that none of the patients had any clinical symptoms or changes in biochemical parameters or inflammatory signs implying immunization. With the aim of assessing changes in parameters such as LVEDV, LVEF, stroke volume, myocardial mass, cardiac output, and change in clinical symptoms in ischemic HF patients treated with CSCC_ASC, a double-blind, placebo-controlled, multicenter study is currently in phase II [63]. The umbilical cord-derived MSCs (UC-MSCs) are easily attainable stem cells and can differentiate into cardiomyocyte-like and ECs in vitro, and also exert paracrine effects that enhance vascular regeneration and cardiomyocyte protection. Due to concerns about the safety of donor cell entrapment in the pulmonary circulation and whether they will achieve their therapeutic effect in a context of low cardiac engraftment, there is limited experience on intravenous administration of MSCs in patients with CVDs [64]. The intravenous delivery of UC-MSCs seems safe and efficient in patients with chronic stable HF [64]. UC-MSC-treated group exhibited significant improvements in the ventricular systolic function, New York Heart Association functional classification (NYHA Classification), and quality of life indices [64] (Table 1).

Table 1. Clinical trials using MSCs to treat cardiac diseases

Disease	Source of MSCs	Administration route	Dose (cell number x 10 ⁶)	Follow-up period (months)	Outcome (improvement in LVEF) (vs. control)	Ref.
AMI	auto-BM-MSCs	IC	48 000- 60 000	6	Yes	53
AMI	allo-BM-MSCs	IV	0.5, 1.6 or 5/kg	6	No	58
AMI	allo-WJMSCs	IC	6	18	Yes	52
AMI	auto-BM-MSCs	IC	72	6	Yes	51
AMI	auto-BM-MSCs	IC	72	4 and 12	Yes	54
IHF	auto-BM-MSCs	IM	53.8	6	Yes	59
HHF	auto-BM-MSCs	IM	600	13	Yes	60
IHD and IHF	allo-ASCs	IM	100	6	Yes	62
ICM or NICM	allo-BM-MPCs	IM	25, 75 or 150	36	No	61
HF	allo-AT-CSCC_ASC	IM	100	6	Yes	63
HF	allo-UC-MSCs	IV	1/kg	12	Yes	64
DCM	allo-BM-MSCs	IM	100	12	No control (yes)	57
	auto-BM-MSCs	IM	100	12	No control	
ICM	auto-BM-MSCs	IM	200	12	No	66
ICM	auto-BM-MSCs	IM	20 or 200	18	No control	67
DCM	auto-BM-MSCs	IC	490	12	Yes	69
ICM	allo-BM-MSCs	IM	20 or 100	12	No control	70
ICM	auto-BM-MSCs	IM	20, 100 or 200	13	No control	68
	allo-BM-MSCs					

Abbreviations: AMI- acute myocardial infarction; IHF- ischemic heart failure; ICM- ischemic cardiomyopathy; NICM- non-ischemic cardiomyopathy; DCM- dilated cardiomyopathy; IHD- ischemic heart disease; IHF- ischemic heart failure; auto- autologous; BM-MSCs- bone marrow-derived mesenchymal stem/stromal cells; allo- allogeneic; WJMSCs- Wharton's jelly-derived mesenchymal stem cells; ASCs- adipose derived stromal cells; MPCs- mesenchymal precursor cells, CSCC_ASC- Cardiology Stem Cell Centre adipose-derived stromal cell; AT- adipose tissue derived; UC-MSC- Umbilical cord-derived mesenchymal stem cells; IC- intracoronary injection; IV- intravenous injection; IM- intramyocardial injection.

MSCs as new agents in cell-based therapy of cardiomyopathy

Progressive disorders most often end with heart transplants and they are known as ischemic cardiomyopathy (ICM) and dilated cardiomyopathy (DCM). Given the fact that MSCs secrete numerous paracrine factors that attenuate these mechanisms and possess immunomodulatory

properties, they are a promising therapy for both forms of cardiomyopathy [65].

For patients with chronic ICM and LV dysfunction, it was shown that transendocardial and intramyocardial injections of autologous MSCs were safe [66,67]. MSCs improved the cardiac structure and function through several mechanisms such as reducing fibrosis and

promoting neoangiogenesis and neomyogenesis [67]. Increased viable myocardial mass and decreased scar size suggested a true MSC-mediated myocardial regeneration [66,67]. Moreover, an improvement in clinical outcomes such as a 6-minute walk test and Minnesota Living with Heart Failure Questionnaire in cardiac patients receiving MSCs therapy was associated with increased LVEF [66,67].

Hare and co. conducted a randomized comparison on the safety and efficacy of allogeneic versus autologous BM-MSCs in patients with cardiomyopathy [57,68]. In both sorts of cardiomyopathies- ICM and DCM, transendocardial injections of allogeneic and autologous MSCs were equally safe without serious adverse events or immunological reactions, additionally propounding that allogeneic MSCs are characteristically immunomodulatory [57,68]. MSCs therapy improved the functional capacity and the quality of life in both clinical entities [57,68]. Several lines of evidence suggested clinically meaningful efficacy and immunosuppressive capacity of allogeneic MSCs compared to autologous MSCs in DCM patients [68]. Through endocrine or paracrine effects, which might promote neovascularization, inhibit cardiomyocyte apoptosis and enhance cardiac repair it is possible to explain the sustained improvement in LVEF, NYHA class, and myocardial perfusion [69]. Interestingly, ventricular remodeling was reversed by both of MSCs- autologous and allogeneic with inverse dose-response [57]. Specifically, in a group of patients with ICM who received lower-doses of MSCs (20 million cells) compared to the group that received 200 million cells, it was found that the first group of patients had significantly greater LVEF, improvement in LVESV, and a reduction in scar size [57]. Due to discrepant and conflicting results, Florea et al. evaluated the relationship between MSCs dose and clinical benefit in patients with ICM [70]. Although both cell doses (20 or 100 million allogeneic BM-MSCs) reduced the scar size, merely the higher dose of MSCs increased EF [70].

MSC-mediated modulation of peripheral artery disease

Peripheral arterial disease (PAD) is a common complication of atherosclerosis. One of the most severe forms of PAD is critical limb ischemia (CLI) which is characterized by rest pain, ischemic ulceration, or gangrene with or without tissue damage [71]. MSCs may improve the consequences of CLI due to their combining potential for inducing angiogenesis and the immunomodulatory environment in situ (Table 2).

During the 24-week follow-up period, the autologous transplantation of BM-MSCs in diabetic patients with CLI and foot ulcers was well tolerated and effective with respect to a few hemodynamic and clinical parameters [72]. In the same study, it was displayed that magnetic resonance angiography scores, Ankle-Brachial Pressure

Index (ABPI), and transcutaneous oxygen pressure before and after the infusion of the cells revealed the increased blood flow, presumable interceded by collateral vessel development [72]. The clinical improvement was verified by ulcer healing rate and painless walking [72]. Posterior to intramuscular administration of allogeneic BM-MSCs (2 million cells/kg) in patients with CLI, significantly improved ankle pressure and ABPI were noticed [73]. There was no utility in the treatment with BM-MSCs for patients with impending amputation [73]. Due to the higher frequency of obtaining the unit of tissue per volume, and larger angiogenic potential compared to BM-MSCs, adipose tissue-derived MSCs (AT-MSCs) have been proposed as feasible approaches for the treatment of disorders related to limb ischemia [74]. A CellDREAM trial displayed that the intramuscular injection of AT-MSCs into the ischemic leg of patients with CLI improved ulcer evolution and wound healing and increased transcutaneous oxygen pressure without any further complications [74]. Besides, a meta-analysis on the usage of stem cell therapy in CLI certified the benefits observed in single studies [75].

Mesenchymal stem cells therapy in stroke

By using the conventional definition of stroke, it can be understood as the abrupt beginning of the loss of focal neurological function due to infarction or hemorrhage in the critical segment of the brain, retina, or spinal cord [76]. It is also important to note that stroke is the leading cause of major disabilities and the second leading cause of death worldwide [77]. Many studies revealed that the application of MSCs in ischemic stroke is secure [78-82], and effective throughout long-term tracking [78-80,82] (Table 2). In the first intracerebral stem cell transplantation study, 18 patients with chronic stroke received a single dose of modified BM-MSCs (SB623) (2.5×10^6 , 5.0×10^6 , or 10×10^6) and demonstrated a significant improvement in the neurological function measured by means of the European Stroke Scale (ESS), the National Institutes of Health Stroke Scale (NIHSS), Fugl-Meyer (F-M) total score, and Fugl-Meyer (F-M) motor function total score at 12 months after the treatment [78].

Lee and co. elucidated that the intravenous application of 5×10^7 autologous MSCs to patients with ischemic stroke improved the clinical parameters that were correlated with the plasma stromal cell-derived factor-1 alpha level at the time of MSC treatment as well as significantly reduced the mortality rate compared to a control group [82]. Levy and co. showed that the intravenous injection of allogeneic MSCs (the same as the autologous transplantation of MSCs) in patients with chronic stroke did not cause any adverse events [80]. MSCs in each dose (0.5, 1.0, and 1.5 million cells/kg body weight) were safe and related to the functional recovery [80].

Table 2. Clinical trials using MSCs in peripheral arterial disease and stroke therapies

Disease	Source of MSCs	Administration route	Dose (cell number x 10 ⁶)	Follow-up period (months)	Outcome	Ref
CLI and foot ulcers	auto-BM-MSCs	IM	930	4	significant improvements in limb perfusion regarding painless walking time, ABI, TcO ₂ , and MRA, and promotion of foot ulcer healing	72
CLI	allo-BM-MSCs	IM	2/kg	24	improvement in rest pain, significant increase in ABPI and ankle pressure, healing of ulcers, and amputation rates	73
CLI	auto AT-MSCs	IM	100	6	TcO ₂ increased, improvement in wound healing	74
chronic stroke	allo-BM-MSCs (SB623)	IC	2.5, 5.0, or 10	12	significant improvement in neurological function in ESS, NIHSS, F-M total score and F-M motor function total score	78
chronic stroke	allo-BM-MSCs	IV	0.5, 1.0, and 1.5/kg	12	significant improvements in NIHSS, BI, MMSE and GDSS	80
ischemic stroke	auto-BM-MSCs	IV	50	60	clinical improvement according to mRS, and level of SDF-1 α	82

Abbreviations: CLI- critical limb ischemia; Auto- autologous; Allo- allogeneic; BM-MSCs- bone marrow-derived mesenchymal stem cells; AT-MSCs- adipose tissue-derived mesenchymal stem cells; IM- intramuscular injection; IV- intravenous injection; ABI- ankle-brachial index; TcO₂- transcutaneous oxygen pressure; MRA- magnetic resonance angiography; ABPI- Ankle Brachial Pressure Index; ESS- European Stroke Scale; NIHSS- National Institutes of Health Stroke Scale; F-M- Fugl-Meyer total score; mRS- modified Rankin Scale; SDF - 1 α - Stromal Derived Factor 1- α ; BI- Bartal score index; MMSE- Mini-Mental Status Exam; GDSS- Geriatric Depression Scale scores.

Conclusions

Mesenchymal stem cells are considered the new therapeutic agents in the treatment of CVDs, on the grounds of their differentiation abilities and paracrine effects. The results obtained in a large number of clinical trials suggest that the local as well as the systemic application of autologous or allogeneic MSCs is a beneficial therapeutic approach for CVDs. Although these studies are paving the way for the development of MSC-based regenerative therapies for structural and functional disorders of the myocardium and blood vessels, the optimal origin and the number of transplanted MSCs as well as the

route of their application should be clearly defined and uniformed in such a way so as to increase the reproducibility and the consistency of the data. Moreover, safety issues regarding MSCs-based therapy are still a matter of debate. The primary concern is the unwanted differentiation of the transplanted MSCs and their potential to suppress the anti-tumor immune response and generate new blood vessels that may promote tumor growth and metastasis [83-86], although some studies displayed opposite results [86]. Therefore, new clinical studies should be focused on the continuous monitoring and the long-term follow-up of MSC-treated patients in order to determine the possible side effects of MSC-based therapy of CVDs.

Conflict of interest disclosure

There are no known conflicts of interest in the publication of this article. The manuscript was read and approved by all authors.

Funding

This study was supported by the Serbian Ministry of Sciences (project number ON 175103), and by Faculty of Medical Sciences, The University of Kragujevac, Serbia (JP 25/19).

Acknowledgments

We would like to thank Andjelka Armus for her help in the preparation and illustration of the figures.

References

1. GBD 2017 Causes of Death Collaborators. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet*. 2018;392(10159):1736-1788. doi: 10.1016/S0140-6736(18)32203-7
2. Flora GD, Nayak MK. A Brief Review of Cardiovascular Diseases, Associated Risk Factors and Current Treatment Regimes. *Curr Pharm Des*. 2019;25(38):4063-4084. doi: 10.2174/1381612825666190925163827
3. Mladěnka P, Applová L, Patočka J, Costa VM, Remiao F, Pourová J, Mladěnka A, Karličková J, Jahodář L, Vopršalová M, Varner KJ, Štěrba M; TOX-OER and CARDIOTOX Hradec Králové Researchers and Collaborators. Comprehensive review of cardiovascular toxicity of drugs and related agents. *Med Res Rev*. 2018 Jul;38(4):1332-1403. doi: 10.1002/med.21476
4. Senst B, Kumar A, Diaz RR. Cardiac Surgery. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2021-forthcoming. <https://www.ncbi.nlm.nih.gov/books/NBK532935/>
5. Howitt SH, Herring M, Malagon I, McCollum CN, Grant SW. Incidence and outcomes of sepsis after cardiac surgery as defined by the Sepsis-3 guidelines. *Br J Anaesth*. 2018 Mar;120(3):509-516. doi: 10.1016/j.bja.2017.10.018
6. Volarevic V, Bojic S, Nurkovic J, Volarevic A, Ljubic B, Arsenijevic N, Lako M, Stojkovic M. Stem cells as new agents for the treatment of infertility: current and future perspectives and challenges. *Biomed Res Int*. 2014;2014:507234. doi: 10.1155/2014/507234
7. Harrell CR, Sadikot R, Pascual J, Fellabaum C, Jankovic MG, Jovicic N, Djonov V, Arsenijevic N, Volarevic V. Mesenchymal Stem Cell-Based Therapy of Inflammatory Lung Diseases: Current Understanding and Future Perspectives. *Stem Cells Int*. 2019;2019:4236973. doi: 10.1155/2019/4236973
8. Otsuru S, Hofmann TJ, Olson TS, Dominici M, Horwitz EM. Improved isolation and expansion of bone marrow mesenchymal stromal cells using a novel marrow filter device. *Cytotherapy*. 2013 Feb;15(2):146-53. doi: 10.1016/j.jcyt.2012.10.012
9. Guasti L, New SE, Hadjidemetriou I, Palmiero M, Ferretti P. Plasticity of human adipose-derived stem cells - relevance to tissue repair. *Int J Dev Biol*. 2018;62(6-7-8):431-439. doi: 10.1387/ijdb.180074pf
10. Tondreau T, Meuleman N, Delforge A, Dejefeffe M, Leroy R, Massy M, Mortier C, Bron D, Lagneaux L. Mesenchymal stem cells derived from CD133-positive cells in mobilized peripheral blood and cord blood: proliferation, Oct4 expression, and plasticity. *Stem Cells*. 2005 Sep;23(8):1105-12. doi: 10.1634/stemcells.2004-0330
11. Tatullo M, Codispoti B, Pacifici A, Palmieri F, Marrelli M, Pacifici L, Paduano F. Potential Use of Human Periapical Cyst-Mesenchymal Stem Cells (hPCy-MSCs) as a Novel Stem Cell Source for Regenerative Medicine Applications. *Front Cell Dev Biol*. 2017 Dec 5;5:103. doi: 10.3389/fcell.2017.00103
12. Cagliani J, Grande D, Molmenti EP, Miller EJ, Rilo HLR. Immunomodulation by Mesenchymal Stromal Cells and Their Clinical Applications. *J Stem Cell Regen Biol*. 2017;3(2):10.15436/2471-0598.17.022. doi: 10.15436/2471-0598.17.022
13. Niezgoda A, Niezgoda P, Nowowiejska L, Bialecka A, Męcińska-Jundziłł K, Adamska U, Czajkowski R. Properties of skin stem cells and their potential clinical applications in modern dermatology. *Eur J Dermatol*. 2017 Jun 1;27(3):227-236. doi: 10.1684/ejd.2017.2988
14. Bojic S, Volarevic V, Ljubic B, Stojkovic M. Dental stem cells--characteristics and potential. *Histol Histopathol*. 2014 Jun;29(6):699-706. doi: 10.14670/HH-29.699
15. Majka M, Sułkowski M, Badyra B, Musiałek P. Concise Review: Mesenchymal Stem Cells in Cardiovascular Regeneration: Emerging Research Directions and Clinical Applications. *Stem Cells Transl Med*. 2017 Oct;6(10):1859-1867. doi: 10.1002/sctm.16-0484
16. Alves da Silva ML, Costa-Pinto AR, Martins A, Correlo VM, Sol P, Bhattacharya M, Faria S, Reis RL, Neves NM. Conditioned medium as a strategy for human stem cells chondrogenic differentiation. *J Tissue Eng Regen Med*. 2015 Jun;9(6):714-23. doi: 10.1002/term.1812
17. Koike C, Zhou K, Takeda Y, Fathy M, Okabe M, Yoshida T, Nakamura Y, Kato Y, Nikaido T. Characterization of amniotic stem cells. *Cell Reprogram*. 2014 Aug;16(4):298-305. doi: 10.1089/cell.2013.0090

18. Goudarzi N, Shabani R, Ebrahimi M, Baghestani A, Dehdashtian E, Vahabzadeh G, Soleimani M, Moradi F, Katebi M. Comparative phenotypic characterization of human colostrum and breast milk-derived stem cells. *Hum Cell*. 2020 Apr;33(2):308-317. doi: 10.1007/s13577-019-00320-x
19. He W, Zhu W, Cao Q, Shen Y, Zhou Q, Yu P, Liu X, Ma J, Li Y, Hong K. Generation of Mesenchymal-Like Stem Cells From Urine in Pediatric Patients. *Transplant Proc*. 2016 Jul-Aug;48(6):2181-5. doi: 10.1016/j.transproceed.2016.02.078
20. Harrell CR, Gazdic M, Fellabaum C, Jovicic N, Djonov V, Arsenijevic N, Volarevic V. Therapeutic Potential of Amniotic Fluid Derived Mesenchymal Stem Cells Based on their Differentiation Capacity and Immunomodulatory Properties. *Curr Stem Cell Res Ther*. 2019;14(4):327-336. doi: 10.2174/1574888X14666190222201749
21. Gazdic M, Arsenijevic A, Markovic BS, Volarevic A, Dimova I, Djonov V, Arsenijevic N, Stojkovic M, Volarevic V. Mesenchymal Stem Cell-Dependent Modulation of Liver Diseases. *Int J Biol Sci*. 2017 Sep 5;13(9):1109-1117. doi: 10.7150/ijbs.20240
22. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, Deans R, Keating A, Prockop Dj, Horwitz E. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. *Cytotherapy*. 2006;8(4):315-7. doi: 10.1080/14653240600855905
23. Toma C, Pittenger MF, Cahill KS, Byrne BJ, Kessler PD. Human mesenchymal stem cells differentiate to a cardiomyocyte phenotype in the adult murine heart. *Circulation*. 2002 Jan 1;105(1):93-8. doi: 10.1161/hc0102.101442
24. Ohnishi S, Yanagawa B, Tanaka K, Miyahara Y, Obata H, Kataoka M, Kodama M, Ishibashi-Ueda H, Kangawa K, Kitamura S, Nagaya N. Transplantation of mesenchymal stem cells attenuates myocardial injury and dysfunction in a rat model of acute myocarditis. *J Mol Cell Cardiol*. 2007 Jan;42(1):88-97. doi: 10.1016/j.yjmcc.2006.10.003
25. Musiał-Wysocka A, Kot M, Sułkowski M, Majka M. Regenerative Potential of the Product "CardioCell" Derived from the Wharton's Jelly Mesenchymal Stem Cells for Treating Hindlimb Ischemia. *Int J Mol Sci*. 2019 Sep 18;20(18):4632. doi: 10.3390/ijms20184632
26. Gong X, Wang P, Wu Q, Wang S, Yu L, Wang G. Human umbilical cord blood derived mesenchymal stem cells improve cardiac function in cTnT(R141W) transgenic mouse of dilated cardiomyopathy. *Eur J Cell Biol*. 2016 Jan;95(1):57-67. doi: 10.1016/j.ejcb.2015.11.003
27. Zhang B, Zhang J, Zhu D, Kong Y. Mesenchymal stem cells rejuvenate cardiac muscle after ischemic injury. *Aging (Albany NY)*. 2019 Jan 6;11(1):63-72. doi: 10.18632/aging.101718
28. Cheng Z, Wang L, Qu M, Liang H, Li W, Li Y, Deng L, Zhang Z, Yang GY. Mesenchymal stem cells attenuate blood-brain barrier leakage after cerebral ischemia in mice. *J Neuroinflammation*. 2018 May 3;15(1):135. doi: 10.1186/s12974-018-1153-1
29. Yao Y, Huang J, Geng Y, Qian H, Wang F, Liu X, Shang M, Nie S, Liu N, Du X, Dong J, Ma C. Paracrine action of mesenchymal stem cells revealed by single cell gene profiling in infarcted murine hearts. *PLoS One*. 2015 Jun 4;10(6):e0129164. doi: 10.1371/journal.pone.0129164
30. Luger D, Lipinski MJ, Westman PC, Glover DK, Dimastromatteo J, Frias JC, Albelda MT, Sikora S, Kharazi A, Vertelov G, Waksman R, Epstein SE. Intravenously Delivered Mesenchymal Stem Cells: Systemic Anti-Inflammatory Effects Improve Left Ventricular Dysfunction in Acute Myocardial Infarction and Ischemic Cardiomyopathy. *Circ Res*. 2017 May 12;120(10):1598-1613. doi: 10.1161/CIRCRESAHA.117.310599
31. Huang YS, Li IH, Chueh SH, Hueng DY, Tai MC, Liang CM, Lien SB, Sytwu HK, Ma KH. Mesenchymal stem cells from rat olfactory bulbs can differentiate into cells with cardiomyocyte characteristics. *J Tissue Eng Regen Med*. 2015 Dec;9(12):E191-201. doi: 10.1002/term.1684
32. Soltani L, Rahmani HR, Daliri Joupari M, Ghaneialvar H, Mahdavi AH, Shamsara M. Ovine fetal mesenchymal stem cell differentiation to cardiomyocytes, effects of co-culture, role of small molecules; reversine and 5-azacytidine. *Cell Biochem Funct*. 2016 Jun;34(4):250-61. doi: 10.1002/cbf.3187
33. Hafez P, Jose S, Chowdhury SR, Ng MH, Ruszymah BH, Abdul Rahman Mohd R. Cardiomyogenic differentiation of human sternal bone marrow mesenchymal stem cells using a combination of basic fibroblast growth factor and hydrocortisone. *Cell Biol Int*. 2016 Jan;40(1):55-64. doi: 10.1002/cbin.10536
34. Joddar B, Kumar SA, Kumar A. A Contact-Based Method for Differentiation of Human Mesenchymal Stem Cells into an Endothelial Cell-Phenotype. *Cell Biochem Biophys*. 2018 Jun;76(1-2):187-195. doi: 10.1007/s12013-017-0828-z
35. Gu W, Hong X, Le Bras A, Nowak WN, Issa Bhaloo S, Deng J, Xie Y, Hu Y, Ruan XZ, Xu Q. Smooth muscle cells differentiated from mesenchymal stem cells are regulated by microRNAs and suitable for vascular tissue grafts. *J Biol Chem*. 2018 May 25;293(21):8089-8102. doi: 10.1074/jbc.RA118.001739

36. Zhang X, Bendeck MP, Simmons CA, Santerre JP. Deriving vascular smooth muscle cells from mesenchymal stromal cells: Evolving differentiation strategies and current understanding of their mechanisms. *Biomaterials*. 2017 Nov;145:9-22. doi: 10.1016/j.biomaterials.2017.08.028
37. Gu W, Hong X, Le Bras A, Nowak WN, Issa Bhaloo S, Deng J, Xie Y, Hu Y, Ruan XZ, Xu Q. Smooth muscle cells differentiated from mesenchymal stem cells are regulated by microRNAs and suitable for vascular tissue grafts. *J Biol Chem*. 2018 May 25;293(21):8089-8102. doi: 10.1074/jbc.RA118.001739
38. White IA, Sanina C, Balkan W, Hare JM. Mesenchymal Stem Cells in Cardiology. *Methods Mol Biol*. 2016;1416:55-87. doi: 10.1007/978-1-4939-3584-0_4
39. Volarevic V, Gazdic M, Simovic Markovic B, Jovicic N, Djonov V, Arsenijevic N. Mesenchymal stem cell-derived factors: Immuno-modulatory effects and therapeutic potential. *Biofactors*. 2017 Sep 10;43(5): 633-644. doi: 10.1002/biof.1374
40. Zhang J, Wu Y, Chen A, Zhao Q. Mesenchymal stem cells promote cardiac muscle repair via enhanced neovascularization. *Cell Physiol Biochem*. 2015; 35(3):1219-29. doi: 10.1159/000373945
41. Ohnishi S, Yanagawa B, Tanaka K, Miyahara Y, Obata H, Kataoka M, Kodama M, Ishibashi-Ueda H, Kangawa K, Kitamura S, Nagaya N. Transplantation of mesenchymal stem cells attenuates myocardial injury and dysfunction in a rat model of acute myocarditis. *J Mol Cell Cardiol*. 2007 Jan;42(1):88-97. doi: 10.1016/j.yjmcc.2006.10.003
42. Markel TA, Wang Y, Herrmann JL, Crisostomo PR, Wang M, Novotny NM, Herring CM, Tan J, Lahm T, Meldrum DR. VEGF is critical for stem cell-mediated cardioprotection and a crucial paracrine factor for defining the age threshold in adult and neonatal stem cell function. *Am J Physiol Heart Circ Physiol*. 2008; 295(6):H2308-14. doi: 10.1152/ajpheart.00565.2008
43. Hatzistergos KE, Quevedo H, Oskoueï BN, Hu Q, Feigenbaum GS, Margitich IS, Mazhari R, Boyle AJ, Zambrano JP, Rodriguez JE, Dulce R, Pattany PM, Valdes D, Revilla C, Heldman AW, McNiece I, Hare JM. Bone marrow mesenchymal stem cells stimulate cardiac stem cell proliferation and differentiation. *Circ Res*. 2010;107(7):913-22. doi: 10.1161/CIRCRESAHA.110.222703
44. Hatzistergos KE, Saur D, Seidler B, Balkan W, Breton M, Valasaki K, Takeuchi LM, Landin AM, Khan A, Hare JM. Stimulatory Effects of Mesenchymal Stem Cells on cKit+ Cardiac Stem Cells Are Mediated by SDF1/CXCR4 and SCF/cKit Signaling Pathways. *Circ Res*. 2016 Sep 30;119(8):921-30. doi: 10.1161/CIRCRESAHA.116.309281
45. Beigi F, Schmeckpeper J, Pow-Anpongkul P, Payne JA, Zhang L, Zhang Z, Huang J, Mirotsov M, Dzau VJ. C3orf58, a novel paracrine protein, stimulates cardiomyocyte cell-cycle progression through the PI3K-AKT-CDK7 pathway. *Circ Res*. 2013;113(4): 372-80. doi: 10.1161/CIRCRESAHA.113.301075
46. Liu X, Chen H, Zhu W, Chen H, Hu X, Jiang Z, Xu Y, Zhou Y, Wang K, Wang L, Chen P, Hu H, Wang C, Zhang N, Ma Q, Huang M, Hu D, Zhang L, Wu R, Wang Y, Xu Q, Yu H, Wang J. Transplantation of SIRT1-engineered aged mesenchymal stem cells improves cardiac function in a rat myocardial infarction model. *J Heart Lung Transplant*. 2014;33(10):1083-92. doi: 10.1016/j.healun.2014.05.008
47. Harrell CR, Jankovic MG, Fellabaum C, Volarevic A, Djonov V, Arsenijevic A, Volarevic V. Molecular Mechanisms Responsible for Anti-inflammatory and Immunosuppressive Effects of Mesenchymal Stem Cell-Derived Factors. *Adv Exp Med Biol*. 2019; 1084:187-206. doi: 10.1007/5584_2018_306
48. Gazdic M, Volarevic V, Arsenijevic N, Stojkovic M. Mesenchymal stem cells: a friend or foe in immune-mediated diseases. *Stem Cell Rev Rep*. 2015 Apr; 11(2):280-7. doi: 10.1007/s12015-014-9583-3
49. Markovic BS, Kanjevac T, Harrell CR, Gazdic M, Fellabaum C, Arsenijevic N, Volarevic V. Molecular and Cellular Mechanisms Involved in Mesenchymal Stem Cell-Based Therapy of Inflammatory Bowel Diseases. *Stem Cell Rev Rep*. 2018 Apr;14(2):153-165. doi: 10.1007/s12015-017-9789-2
50. Molina EJ, Palma J, Gupta D, Torres D, Gaughan JP, Houser S, Macha M. Reverse remodeling is associated with changes in extracellular matrix proteases and tissue inhibitors after mesenchymal stem cell (MSC) treatment of pressure overload hypertrophy. *J Tissue Eng Regen Med*. 2009 Feb;3(2):85-91. doi: 10.1002/term.137
51. Lee JW, Lee SH, Youn YJ, Ahn MS, Kim JY, Yoo BS, Yoon J, Kwon W, Hong IS, Lee K, Kwan J, Park KS, Choi D, Jang YS, Hong MK. A randomized, open-label, multicenter trial for the safety and efficacy of adult mesenchymal stem cells after acute myocardial infarction. *J Korean Med Sci*. 2014 Jan;29(1):23-31. doi: 10.3346/jkms.2014.29.1.23
52. Gao LR, Chen Y, Zhang NK, Yang XL, Liu HL, Wang ZG, Yan XY, Wang Y, Zhu ZM, Li TC, Wang LH, Chen HY, Chen YD, Huang CL, Qu P, Yao C, Wang B, Chen GH, Wang ZM, Xu ZY, Bai J, Lu D, Shen YH, Guo F, Liu MY, Yang Y, Ding YC, Yang Y, Tian HT, Ding QA, Li LN, Yang XC, Hu X. Intracoronary infusion of Wharton's jelly-derived mesenchymal stem cells in acute myocardial infarction: double-blind, randomized controlled trial. *BMC Med*. 2015 Jul 10;13:162. doi: 10.1186/s12916-015-0399-z

53. Chen SL, Fang WW, Ye F, Liu YH, Qian J, Shan SJ, Zhang JJ, Chunhua RZ, Liao LM, Lin S, Sun JP. Effect on left ventricular function of intracoronary transplantation of autologous bone marrow mesenchymal stem cell in patients with acute myocardial infarction. *Am J Cardiol.* 2004 Jul 1; 94(1):92-5. doi: 10.1016/j.amjcard.2004.03.034
54. Kim SH, Cho JH, Lee YH, Lee JH, Kim SS, Kim MY, Lee MG, Kang WY, Lee KS, Ahn YK, Jeong MH, Kim HS. Improvement in Left Ventricular Function with Intracoronary Mesenchymal Stem Cell Therapy in a Patient with Anterior Wall ST-Segment Elevation Myocardial Infarction. *Cardiovasc Drugs Ther.* 2018 Aug;32(4):329-338. doi: 10.1007/s10557-018-6804-z
55. Katritsis DG, Sotiropoulou P, Giazitzoglou E, Karvouni E, Papamichail M. Electrophysiological effects of intracoronary transplantation of autologous mesenchymal and endothelial progenitor cells. *Europace.* 2007 Mar;9(3):167-71. doi: 10.1093/europace/eul184
56. Golpanian S, Wolf A, Hatzistergos KE, Hare JM. Rebuilding the Damaged Heart: Mesenchymal Stem Cells, Cell-Based Therapy, and Engineered Heart Tissue. *Physiol Rev.* 2016 Jul;96(3):1127-68. doi: 10.1152/physrev.00019.2015
57. Hare JM, DiFede DL, Rieger AC, Florea V, Landin AM, El-Khorazaty J, Khan A, Mushtaq M, Lowery MH, Byrnes JJ, Hendel RC, Cohen MG, Alfonso CE, Valasaki K, Pujol MV, Golpanian S, Ghersin E, Fishman JE, Pattany P, Gomes SA, Delgado C, Miki R, Abuzeid F, Vidro-Casiano M, Premer C, Medina A, Porras V, Hatzistergos KE, Anderson E, Mendizabal A, Mitrani R, Heldman AW. Randomized Comparison of Allogeneic Versus Autologous Mesenchymal Stem Cells for Nonischemic Dilated Cardiomyopathy: POSEIDON-DCM Trial. *J Am Coll Cardiol.* 2017 Feb 7;69(5):526-537. doi: 10.1016/j.jacc.2016.11.009
58. Hare JM, Traverse JH, Henry TD, Dib N, Strumpf RK, Schulman SP, Gerstenblith G, DeMaria AN, Denktas AE, Gammon RS, Hermiller JB Jr, Reisman MA, Schaer GL, Sherman W. A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction. *J Am Coll Cardiol.* 2009 Dec 8;54(24):2277-86. doi: 10.1016/j.jacc.2009.06.055
59. Mathiasen AB, Qayyum AA, Jørgensen E, Helqvist S, Fischer-Nielsen A, Kofoed KF, Haack-Sørensen M, Eklund A, Kastrup J. Bone marrow-derived mesenchymal stromal cell treatment in patients with severe ischaemic heart failure: a randomized placebo-controlled trial (MSC-HF trial). *Eur Heart J.* 2015 Jul 14;36(27):1744-53. doi: 10.1093/eurheartj/ehv136
60. Teerlink JR, Metra M, Filippatos GS, Davison BA, Bartunek J, Terzic A, Gersh BJ, Povsic TJ, Henry TD, Alexandre B, Homsy C, Edwards C, Seron A, Wijns W, Cotter G; CHART Investigators. Benefit of cardiopoietic mesenchymal stem cell therapy on left ventricular remodelling: results from the Congestive Heart Failure Cardiopoietic Regenerative Therapy (CHART-1) study. *Eur J Heart Fail.* 2017 Nov;19(11):1520-1529. doi: 10.1002/ejhf.898
61. Perin EC, Borow KM, Silva GV, DeMaria AN, Marroquin OC, Huang PP, Traverse JH, Krum H, Skerrett D, Zheng Y, Willerson JT, Itescu S, Henry TD. A Phase II Dose-Escalation Study of Allogeneic Mesenchymal Precursor Cells in Patients With Ischemic or Nonischemic Heart Failure. *Circ Res.* 2015; 117(6):576-84. doi: 10.1161/CIRCRESAHA.115.306332
62. Kastrup J, Haack-Sørensen M, Juhl M, Harary Søndergaard R, Follin B, Drozd Lund L, Mønsted Johansen E, Ali Qayyum A, Bruun Mathiasen A, Jørgensen E, Helqvist S, Jørgen Elberg J, Bruunsgaard H, Eklund A. Cryopreserved Off-the-Shelf Allogeneic Adipose-Derived Stromal Cells for Therapy in Patients with Ischemic Heart Disease and Heart Failure-A Safety Study. *Stem Cells Transl Med.* 2017 Nov;6(11):1963-1971. doi: 10.1002/sctm.17-0040
63. Kastrup J, Schou M, Gustafsson I, Nielsen OW, Møgelvang R, Kofoed KF, Kragelund C, Hove JD, Fabricius-Bjerre A, Heitman M, Haack-Sørensen M, Lund LD, Johansen EM, Qayyum AA, Mathiasen AB, Eklund A. Rationale and Design of the First Double-Blind, Placebo-Controlled Trial with Allogeneic Adipose Tissue-Derived Stromal Cell Therapy in Patients with Ischemic Heart Failure: A Phase II Danish Multicentre Study. *Stem Cells Int.* 2017;2017:8506370. doi: 10.1155/2017/8506370
64. Bartolucci J, Verdugo FJ, González PL, Larrea RE, Abarzua E, Goset C, Rojo P, Palma I, Lamich R, Pedreros PA, Valdivia G, Lopez VM, Nazzari C, Alcayaga-Miranda F, Cuenca J, Brobeck MJ, Patel AN, Figueroa FE, Khoury M. Safety and Efficacy of the Intravenous Infusion of Umbilical Cord Mesenchymal Stem Cells in Patients With Heart Failure: A Phase 1/2 Randomized Controlled Trial (RIMECARD Trial [Randomized Clinical Trial of Intravenous Infusion Umbilical Cord Mesenchymal Stem Cells on Cardiopathy]). *Circ Res.* 2017 Oct 27;121(10):1192-1204. doi: 10.1161/CIRCRESAHA.117.310712
65. Tompkins BA, Rieger AC, Florea V, Banerjee MN, Natsumeda M, Nigh ED, Landin AM, Rodriguez GM, Hatzistergos KE, Schulman IH, Hare JM. Comparison of Mesenchymal Stem Cell Efficacy in Ischemic Versus Nonischemic Dilated Cardiomyopathy. *J Am Heart Assoc.* 2018 Jul 12;7(14):e008460. doi: 10.1161/JAHA.117.008460

66. Heldman AW, DiFede DL, Fishman JE, Zambrano JP, Trachtenberg BH, Karantalis V, Mushtaq M, Williams AR, Suncion VY, McNiece IK, Ghersin E, Soto V, Lopera G, Miki R, Willens H, Hendel R, Mitrani R, Pattany P, Feigenbaum G, Oskouei B, Byrnes J, Lowery MH, Sierra J, Pujol MV, Delgado C, Gonzalez PJ, Rodriguez JE, Bagno LL, Rouy D, Altman P, Foo CW, da Silva J, Anderson E, Schwarz R, Mendizabal A, Hare JM. Transendocardial mesenchymal stem cells and mononuclear bone marrow cells for ischemic cardiomyopathy: the TAC-HFT randomized trial. *JAMA*. 2014 Jan 1;311(1):62-73. doi: 10.1001/jama.2013.282909
67. Karantalis V, DiFede DL, Gerstenblith G, Pham S, Symes J, Zambrano JP, Fishman J, Pattany P, McNiece I, Conte J, Schulman S, Wu K, Shah A, Breton E, Davis-Sproul J, Schwarz R, Feigenbaum G, Mushtaq M, Suncion VY, Lardo AC, Borrello I, Mendizabal A, Karas TZ, Byrnes J, Lowery M, Heldman AW, Hare JM. Autologous mesenchymal stem cells produce concordant improvements in regional function, tissue perfusion, and fibrotic burden when administered to patients undergoing coronary artery bypass grafting: The Prospective Randomized Study of Mesenchymal Stem Cell Therapy in Patients Undergoing Cardiac Surgery (PROMETHEUS) trial. *Circ Res*. 2014;114(8): 1302-10. doi: 10.1161/CIRCRESAHA.114.303180
68. Hare JM, Fishman JE, Gerstenblith G, DiFede Velazquez DL, Zambrano JP, Suncion VY, Tracy M, Ghersin E, Johnston PV, Brinker JA, Breton E, Davis-Sproul J, Schulman IH, Byrnes J, Mendizabal AM, Lowery MH, Rouy D, Altman P, Wong Po Foo C, Ruiz P, Amador A, Da Silva J, McNiece IK, Heldman AW, George R, Lardo A. Comparison of allogeneic vs autologous bone marrow-derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: the POSEIDON randomized trial. *JAMA*. 2012 Dec 12;308(22):2369-79. doi: 10.1001/jama.2012.25321
69. Xiao W, Guo S, Gao C, Dai G, Gao Y, Li M, Wang X, Hu D. A Randomized Comparative Study on the Efficacy of Intracoronary Infusion of Autologous Bone Marrow Mononuclear Cells and Mesenchymal Stem Cells in Patients With Dilated Cardiomyopathy. *Int Heart J*. 2017 Apr 6;58(2):238-244. doi: 10.1536/ihj.16-328
70. Florea V, Rieger AC, DiFede DL, El-Khorazaty J, Natsumeda M, Banerjee MN, Tompkins BA, Khan A, Schulman IH, Landin AM, Mushtaq M, Golpanian S, Lowery MH, Byrnes JJ, Hendel RC, Cohen MG, Valasaki K, Pujol MV, Ghersin E, Miki R, Delgado C, Abuzeid F, Vidro-Casiano M, Saltzman RG, DaFonseca D, Caceres LV, Ramdas KN, Mendizabal A, Heldman AW, Mitrani RD, Hare JM. Dose Comparison Study of Allogeneic Mesenchymal Stem Cells in Patients With Ischemic Cardiomyopathy (The TRIDENT Study). *Circ Res*. 2017 Nov 10;121(11):1279-1290. doi: 10.1161/CIRCRESAHA.117.311827
71. Subherwal S, Patel MR, Kober L, Peterson ED, Bhatt DL, Gislason GH, Olsen AM, Jones WS, Torp-Pedersen C, Fosbol EL. Peripheral artery disease is a coronary heart disease risk equivalent among both men and women: results from a nationwide study. *Eur J Prev Cardiol*. 2015 Mar;22(3):317-25. doi: 10.1177/2047487313519344
72. Lu D, Chen B, Liang Z, Deng W, Jiang Y, Li S, Xu J, Wu Q, Zhang Z, Xie B, Chen S. Comparison of bone marrow mesenchymal stem cells with bone marrow-derived mononuclear cells for treatment of diabetic critical limb ischemia and foot ulcer: a double-blind, randomized, controlled trial. *Diabetes Res Clin Pract*. 2011;92(1):26-36. doi: 10.1016/j.diabres.2010.12.010
73. Gupta PK, Chullikana A, Parakh R, Desai S, Das A, Gottipamula S, Krishnamurthy S, Anthony N, Pherwani A, Majumdar AS. A double blind randomized placebo controlled phase I/II study assessing the safety and efficacy of allogeneic bone marrow derived mesenchymal stem cell in critical limb ischemia. *J Transl Med*. 2013 Jun 10;11:143. doi: 10.1186/1479-5876-11-143
74. Bura A, Planat-Benard V, Bourin P, Silvestre JS, Gross F, Grolleau JL, Saint-Lebesse B, Peyrafitte JA, Fleury S, Gadelorge M, Taurand M, Dupuis-Coronas S, Leobon B, Casteilla L. Phase I trial: the use of autologous cultured adipose-derived stroma/stem cells to treat patients with non-revascularizable critical limb ischemia. *Cytotherapy*. 2014 Feb;16(2):245-57. doi: 10.1016/j.jcyt.2013.11.011
75. Xie B, Luo H, Zhang Y, Wang Q, Zhou C, Xu D. Autologous Stem Cell Therapy in Critical Limb Ischemia: A Meta-Analysis of Randomized Controlled Trials. *Stem Cells Int*. 2018 May 24;2018:7528464. doi: 10.1155/2018/7528464
76. Sacco RL, Kasner SE, Broderick JP, Caplan LR, Connors JJ, Culebras A, Elkind MS, George MG, Hamdan AD, Higashida RT, Hoh BL, Janis LS, Kase CS, Kleindorfer DO, Lee JM, Moseley ME, Peterson ED, Turan TN, Valderrama AL, Vinters HV; American Heart Association Stroke Council, Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular Radiology and Intervention; Council on Cardiovascular and Stroke Nursing; Council on Epidemiology and Prevention; Council on Peripheral Vascular Disease; Council on Nutrition, Physical Activity and Metabolism. An updated definition of stroke for the 21st century: a statement for healthcare professionals from the

- American Heart Association/American Stroke Association. *Stroke*. 2013 Jul;44(7):2064-89. doi: 10.1161/STR.0b013e318296aeca
77. Johnson W, Onuma O, Owolabi M, Sachdev S. Stroke: a global response is needed. *Bull World Health Organ*. 2016;94(9):634-634A. doi: 10.2471/BLT.16.181636
78. Steinberg GK, Kondziolka D, Wechsler LR, Lunsford LD, Coburn ML, Billigen JB, Kim AS, Johnson JN, Bates D, King B, Case C, McGrogan M, Yankee EW, Schwartz NE. Clinical Outcomes of Transplanted Modified Bone Marrow-Derived Mesenchymal Stem Cells in Stroke: A Phase 1/2a Study. *Stroke*. 2016; 47(7):1817-24. doi: 10.1161/STROKEAHA.116.012995
79. Hess DC, Wechsler LR, Clark WM, Savitz SI, Ford GA, Chiu D, Yavagal DR, Uchino K, Liebeskind DS, Auchus AP, Sen S, Sila CA, Vest JD, Mays RW. Safety and efficacy of multipotent adult progenitor cells in acute ischaemic stroke (MASTERS): a randomised, double-blind, placebo-controlled, phase 2 trial. *Lancet Neurol*. 2017 May;16(5):360-368. doi: 10.1016/S1474-4422(17)30046-7
80. Levy ML, Crawford JR, Dib N, Verkh L, Tankovich N, Cramer SC. Phase I/II Study of Safety and Preliminary Efficacy of Intravenous Allogeneic Mesenchymal Stem Cells in Chronic Stroke. *Stroke*. 2019 Oct;50(10):2835-2841. doi: 10.1161/STROKEAHA.119.026318
81. Savitz SI, Yavagal D, Rappard G, Likosky W, Rutledge N, Graffagnino C, Alderazi Y, Elder JA, Chen PR, Budzik RF Jr, Tarrel R, Huang DY, Hinson JM Jr. A Phase 2 Randomized, Sham-Controlled Trial of Internal Carotid Artery Infusion of Autologous Bone Marrow-Derived ALD-401 Cells in Patients With Recent Stable Ischemic Stroke (RECOVER-Stroke). *Circulation*. 2019 Jan 8;139(2):192-205. doi: 10.1161/CIRCULATIONAHA.117.030659
82. Lee JS, Hong JM, Moon GJ, Lee PH, Ahn YH, Bang OY; STARTING collaborators. A long-term follow-up study of intravenous autologous mesenchymal stem cell transplantation in patients with ischemic stroke. *Stem Cells*. 2010 Jun;28(6):1099-106. doi: 10.1002/stem.430
83. Ljubic B, Milovanovic M, Volarevic V, Murray B, Bugarski D, Przyborski S, Arsenijevic N, Lukic ML, Stojkovic M. Human mesenchymal stem cells creating an immunosuppressive environment and promote breast cancer in mice. *Sci Rep*. 2013;3:2298. doi: 10.1038/srep02298
84. Gazdic M, Simovic Markovic B, Jovicic N, Misirkic-Marjanovic M, Djonov V, Jakovljevic V, Arsenijevic N, Lukic ML, Volarevic V. Mesenchymal Stem Cells Promote Metastasis of Lung Cancer Cells by Downregulating Systemic Antitumor Immune Response. *Stem Cells Int*. 2017;2017:6294717. doi: 10.1155/2017/6294717
85. Volarevic V, Markovic BS, Gazdic M, Volarevic A, Jovicic N, Arsenijevic N, Armstrong L, Djonov V, Lako M, Stojkovic M. Ethical and Safety Issues of Stem Cell-Based Therapy. *Int J Med Sci*. 2018 Jan 1;15(1):36-45. doi: 10.7150/ijms.21666
86. Miloradovic D, Miloradovic D, Markovic BS, Acovic A, Harrell CR, Djonov V, Arsenijevic N, Volarevic V. The Effects of Mesenchymal Stem Cells on Antimelanoma Immunity Depend on the Timing of Their Administration. *Stem Cells Int*. 2020 Jul 10;2020:8842659. doi: 10.1155/2020/8842659